On 12 Nov 2026 GE HealthCare closed at $81.84, -0.0% this year; market cap $37.07bn, P/E 17.1.
Health Care · Health Care Equipment · NASDAQ · United States
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
| Market cap | $37.07bn |
| P/E (trailing) | 17.1 |
| EPS (TTM) | $4.78 |
| Beta | 0.77 |
| Dividend | $0.16 |
| Dividend yield | 0.20% |
| Ex-dividend date | 23 Oct 2026 |
| Latest report | 28 Oct 2026 |
| Next earnings | 27 Jan 2027 |
| YTD | -0.0% |
| 1Y | +9.4% |
| 3Y | +5.5% |
| 5Y | — |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $20.62bn | $2.08bn | $1.51bn |
| 2024 | $19.67bn | $1.99bn | $1.55bn |
| 2023 | $19.55bn | $3.10bn | $1.71bn |
| 2022 | $18.34bn | $1.92bn | $1.80bn |
| 2021 | $17.59bn | $2.25bn | $1.36bn |
We publish no single base value for GE HealthCare. Our valuation methods put it between $70.26 and $91.91 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.